Mannon P, Reinisch W. Interleukin 13 and its role in gut defence and inflammation. Gut 2012;61:1765-73.
Weigmann B, Lehr HA, Yancopoulos G, et al. The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med 2008;205:2099-110.
Kasaian MT, Page KM, Fish S, et al. Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice. Immunology 2014;143:416-27.
Reinisch W, Panés J, Khurana S, et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut 2015;64:894-900.
Danese S, Rudzinski J, Brandt W. Tralokinumab for moderate-To-severe UC: A randomised, double-blind, placebo-controlled, phase IIa study. Gut 2015;64:243-9.
Tilg H, Kaser A. Failure of interleukin 13 blockade in ulcerative colitis. Gut 2015;64:857-8.
Heller F, Fuss IJ, Nieuwenhuis EE, et al. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38.
Hoving JC, Kirstein F, Nieuwenhuizen NE, et al. B cells that produce immunoglobulin E mediate colitis in BALB/c mice. Gastroenterology 2012;142:96-108.
Boirivant M, Fuss IJ, Chu A, et al. Oxazolone colitis: A murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998;188:1929-39.
Mohrs M, Ledermann B, Köhler G, et al. Differences between IL-4-And IL-4 receptor alpha-deficient mice in chronic leishmaniasis reveal a protective role for IL-13 receptor signalling. J Immunol 1999;162:7302-8.
Hoving JC, Nieuwenhuizen NE, Schäfer G, et al. IL-13 signals independent of IL-4 receptor-Alpha chain to drive ovalbumin-induced dermatitis. J Invest Dermatol 2016;136:1286-90.
